Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA appropriations

This article was originally published in The Gray Sheet

Executive Summary

Device center program funding levels increase $13.9 mil. from FY 2001 under Senate Appropriations Committee bill (S 1191). The amount is consistent with FDA estimates for bringing review times within statutory requirements in the short term. The measure, adopted by the Senate Oct. 25, earmarks $178.8 mil. for CDRH and for related field activities in the Office of Regulatory Affairs. The House version, passed in June, includes roughly $179.5 mil. for CDRH (1"The Gray Sheet" June 18, 2001, In Brief)...

You may also be interested in...



Novavax May Seek COVID-19 Vaccine Emergency Authorization In US Based On UK Data

With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.

Novavax May Seek COVID-19 Vaccine Emergency Authorization In US Based On UK Data

With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.

Biogen And Sage On Plans To Build A Brain Franchise Together

The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel